Skip to content

Central pain location in SCN9A-associated SFN: an fMRI pilot study.

Central pain location in SCN9A-associated SFN: an fMRI pilot study. - fMRI in small fiber neuropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47720
Enrollment
60
Registered
2015-11-02
Start date
2018-05-29
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small fiber neuropathyhttps://www.toetsingonline.nl/to/ccmo_monitor.nsf/allabrs/53441-06?EditDocument#

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient group (SCN9A-associated SFN) (n

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: a. Major depression according to DSM-V criteria or a history of major psychiatric disease. b. (History with) alcohol abuse c. Hospital Anxiety and Depression Scale (HADS) * 14 d. Subjects who have another pain syndrome than small fiber neuropathy. e. Contraindications for undergoing MRI: pacemaker, metallic foreign body (including aneurysm clip in the brain), claustrophobia, pregnancy, neurostimulator, pacemaker or other kinds of implanted devices or insulin pump. In case of cardiac valve replacement of ossicular replacement prosthesis the radiologist will be consulted.

Design outcomes

Primary

MeasureTime frame
Concerning the fMRI, change of connectivity in the central executive network (CEN) and sensorimotor network (SMN) is the primary endpoint. Change in brain connectivity have been observed in several neuropathic pain conditions affecting mainly the networks mentioned above: SMN tend to show hyperconnectivity while CEN hipoconnectivity. Concerning DTI, the study parameters are fractional anisotropy (FA) and axial diffusivity (AD).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)